{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:00:05Z","timestamp":1790794805250,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Health Research Imperial Biomedical Research Centre","award":["MR\/Z504002\/1"],"award-info":[{"award-number":["MR\/Z504002\/1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The incidence of inflammatory bowel disease (IBD) in older adults is rising. Studies of late-onset (LO) (diagnosis \u2009\u226560\u2009years of age) IBD are contradictory, with some suggesting increased use of corticosteroid and reduced use of advanced therapies. This multicenter study assessed disease phenotype and therapeutic choice in LO-IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients recruited to the NIHR IBD BioResource with LO ulcerative colitis (UC) or Crohn\u2019s disease (CD) were compared with those with young-onset (YO) (16-39\u2009years of age) and mid-onset (MO) (40-59\u2009years of age) IBD. Medication use and surgeries were assessed in propensity score\u2013matched cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 32\u2009012 patients were studied: 16\u2009930 UC (2247 LO) and 15\u2009082 CD (1409 LO). LO-UC was mostly left-sided, with less isolated proctitis. LO-CD patients had less ileocolonic and perianal disease. Corticosteroid, immunomodulator, and anti-tumor necrosis factor \u03b1 (anti-TNF) use was lower in LO-UC and LO-CD; however, there was no difference in time to colectomy (LO-UC) or intestinal resection (LO-CD) compared with younger patients. LO-CD patients were more likely to receive vedolizumab and ustekinumab than YO-CD (odds ratio, 0.34 [95% confidence interval, 0.18-0.61] and 0.29 [95% confidence interval, 0.09-0.76], respectively). LO patients with perianal CD were less likely to receive anti-tumor necrosis factor or undergo perianal surgery than YO and MO patients with perianal CD (all P\u2009&amp;lt;\u2009.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LO-IBD has a distinct phenotype, with less isolated proctitis (LO-UC) and less ileocolonic and perianal CD. LO-IBD patients had lower corticosteroid, immunomodulator, and anti-tumor necrosis factor use but equivalent colectomy and intestinal resection rates. LO-CD is notable for the higher use of vedolizumab and ustekinumab, suggesting that age, comorbidity, and disease phenotype affect biologic choice in older adults. Research to understand whether differential treatment of older adults is justified is crucial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag072","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:51:26Z","timestamp":1775130686000},"page":"1888-1897","source":"Crossref","is-referenced-by-count":0,"title":["Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-4714","authenticated-orcid":false,"given":"Peter F G","family":"Foulser","sequence":"first","affiliation":[{"name":"Department of Metabolism, Digestion and Reproduction, Imperial College London, W2 1NY , London,","place":["United Kingdom"]},{"name":"Department of Gastroenterology and Hepatology, Imperial College Healthcare NHS Trust , London, W2 1NY,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5271-9672","authenticated-orcid":false,"given":"Laura","family":"Martinez-Gili","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Digestion and Reproduction, Imperial College London, W2 1NY , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-8528","authenticated-orcid":false,"given":"Sharmili","family":"Balarajah","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Digestion and Reproduction, Imperial College London, W2 1NY , London,","place":["United Kingdom"]},{"name":"Department of Gastroenterology and Hepatology, Imperial College Healthcare NHS Trust , London, W2 1NY,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Sundramoorthi","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Digestion and Reproduction, Imperial College London, W2 1NY , London,","place":["United Kingdom"]},{"name":"Department of Gastroenterology and Hepatology, Imperial College Healthcare NHS Trust , London, W2 1NY,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8542-327X","authenticated-orcid":false,"given":"James L","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Digestion and Reproduction, Imperial College London, W2 1NY , London,","place":["United Kingdom"]},{"name":"Department of Gastroenterology and Hepatology, Imperial College Healthcare NHS Trust , London, W2 1NY,","place":["United Kingdom"]},{"name":"Department of Gastroenterology, London North West University Healthcare Trust , London, HA1 3UJ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6300-3100","authenticated-orcid":false,"given":"Benjamin H","family":"Mullish","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Digestion and Reproduction, Imperial College London, W2 1NY , London,","place":["United Kingdom"]},{"name":"Department of Gastroenterology and Hepatology, Imperial College Healthcare NHS Trust , London, W2 1NY,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-5239","authenticated-orcid":false,"given":"Julian R","family":"Marchesi","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Digestion and Reproduction, Imperial College London, W2 1NY , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Parkes","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge , Cambridge, CB2 0AW,","place":["United Kingdom"]},{"name":"Department of Gastroenterology, Cambridge University Hospitals NHS Trust , Cambridge, CB2 0QQ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3358-663X","authenticated-orcid":false,"given":"Timothy R","family":"Orchard","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Digestion and Reproduction, Imperial College London, W2 1NY , London,","place":["United Kingdom"]},{"name":"Department of Gastroenterology and Hepatology, Imperial College Healthcare NHS Trust , London, W2 1NY,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3065-1635","authenticated-orcid":false,"given":"Lucy C","family":"Hicks","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Digestion and Reproduction, Imperial College London, W2 1NY , London,","place":["United Kingdom"]},{"name":"Department of Gastroenterology and Hepatology, Imperial College Healthcare NHS Trust , London, W2 1NY,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5889-7584","authenticated-orcid":false,"given":"Horace R T","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Digestion and Reproduction, Imperial College London, W2 1NY , London,","place":["United Kingdom"]},{"name":"Department of Gastroenterology and Hepatology, Imperial College Healthcare NHS Trust , London, W2 1NY,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"UK IBD BioResource Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F G","family":"Foulser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Martinez-Gili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmili","family":"Balarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Sundramoorthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H","family":"Mullish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian R","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Parkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy C","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horace R T","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2026093014384415700_izag072-B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2019.0377","article-title":"Global ageing: successes, challenges and opportunities","volume":"81","author":"Mitchell","year":"2020","journal-title":"Br J Hosp Med (Lond)"},{"key":"2026093014384415700_izag072-B2","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"2026093014384415700_izag072-B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0889-8553(01)00002-4","article-title":"Epidemiology of inflammatory bowel disease","volume":"31","author":"Loftus","year":"2002","journal-title":"Gastroenterol Clin North Am"},{"key":"2026093014384415700_izag072-B4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026093014384415700_izag072-B5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1053\/j.gastro.2019.01.002","article-title":"Past and future burden of inflammatory bowel diseases based on modeling of population-based data","volume":"156","author":"Coward","year":"2019","journal-title":"Gastroenterology"},{"key":"2026093014384415700_izag072-B6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/ecco-jcc\/jjw188","article-title":"European Crohn\u2019s and Colitis organisation topical review on IBD in the elderly","volume":"11","author":"Sturm","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026093014384415700_izag072-B7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/gutjnl-2012-303864","article-title":"Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study","volume":"63","author":"Charpentier","year":"2014","journal-title":"Gut"},{"key":"2026093014384415700_izag072-B8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/apt.17520","article-title":"Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries-A nationwide cohort study","volume":"58","author":"Norgard","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026093014384415700_izag072-B9","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.dld.2024.02.002","article-title":"Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. a Norwegian nationwide population-based registry study","volume":"56","author":"Anisdahl","year":"2024","journal-title":"Dig Liver Dis"},{"key":"2026093014384415700_izag072-B10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/MIB.0000000000000993","article-title":"Risk of surgery and mortality in elderly-onset inflammatory bowel disease: a population-based cohort study","volume":"23","author":"Nguyen","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026093014384415700_izag072-B11","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.cgh.2025.01.020","article-title":"Risk of age-related and disease-related complications and mortality in elderly-onset inflammatory bowel disease - a population-based study","volume":"23","author":"Ben Hur","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026093014384415700_izag072-B12","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/ecco-jcc\/jjw054","article-title":"Systematic review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease","volume":"10","author":"Ananthakrishnan","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2026093014384415700_izag072-B13","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.cgh.2020.02.048","article-title":"Progression of elderly onset inflammatory bowel diseases: a systematic review and meta-analysis of population-based cohort studies","volume":"18","author":"Rozich","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026093014384415700_izag072-B14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/j.gastro.2017.10.034","article-title":"Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden","volume":"154","author":"Everhov","year":"2018","journal-title":"Gastroenterology"},{"key":"2026093014384415700_izag072-B15","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1016\/S2666-7568(22)00060-5","article-title":"Is it time to include older adults in inflammatory bowel disease trials? A call for action","volume":"3","author":"Vieujean","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"2026093014384415700_izag072-B16","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/MIB.0000000000000747","article-title":"Medication utilization and the impact of continued corticosteroid use on patient-reported outcomes in older patients with inflammatory bowel disease","volume":"22","author":"Geisz","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026093014384415700_izag072-B17","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2026093014384415700_izag072-B18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026093014384415700_izag072-B19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ibd.23026","article-title":"Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease","volume":"19","author":"Desai","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2026093014384415700_izag072-B20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/ecco-jcc\/jjaa012","article-title":"Increased discontinuation rates of anti-TNF therapy in elderly inflammatory bowel disease patients","volume":"14","author":"de Jong","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026093014384415700_izag072-B21","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/apt.15214","article-title":"Early combined immunosuppression may be effective and safe in older patients with Crohn\u2019s disease: post hoc analysis of REACT","volume":"49","author":"Singh","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026093014384415700_izag072-B22","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1097\/MCG.0000000000001458","article-title":"High rates of mortality in geriatric patients admitted for inflammatory bowel disease management","volume":"56","author":"Schwartz","year":"2022","journal-title":"J Clin Gastroenterol"},{"key":"2026093014384415700_izag072-B23","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1136\/gutjnl-2019-318835","article-title":"IBD BioResource: an open-access platform of 25\u2009000 patients to accelerate research in Crohn\u2019s and Colitis","volume":"68","author":"Parkes","year":"2019","journal-title":"Gut"},{"key":"2026093014384415700_izag072-B24","doi-asserted-by":"publisher","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19 Suppl A","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol."},{"key":"2026093014384415700_izag072-B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Soft"},{"key":"2026093014384415700_izag072-B26","year":"2008"},{"key":"2026093014384415700_izag072-B27","year":"2015"},{"key":"2026093014384415700_izag072-B28","year":"2015"},{"key":"2026093014384415700_izag072-B29","year":"2017"},{"key":"2026093014384415700_izag072-B30","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.cgh.2024.08.011","article-title":"Epidemiology of elderly onset IBD: a nationwide population-based cohort study","volume":"23","author":"Singh","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026093014384415700_izag072-B31","doi-asserted-by":"publisher","first-page":"e008597","DOI":"10.1136\/bmjopen-2015-008597","article-title":"Biological and steroid use in relationship to quality measures in older patients with inflammatory bowel disease: a US Medicare cohort study","volume":"5","author":"Johnson","year":"2015","journal-title":"BMJ Open"},{"key":"2026093014384415700_izag072-B32","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1038\/ajg.2014.313","article-title":"Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases","volume":"109","author":"Brassard","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2026093014384415700_izag072-B33","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/MIB.0000000000001031","article-title":"Do thiopurines reduce the risk of surgery in elderly onset inflammatory bowel disease? a 20-year national population-based cohort study","volume":"23","author":"Alexakis","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026093014384415700_izag072-B34","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.dld.2022.12.024","article-title":"Management of inflammatory bowel disease in the elderly: A review","volume":"55","author":"Sousa","year":"2023","journal-title":"Dig Liver Dis"},{"key":"2026093014384415700_izag072-B35","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","article-title":"Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"17","author":"Borren","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026093014384415700_izag072-B36","doi-asserted-by":"publisher","first-page":"e2234200","DOI":"10.1001\/jamanetworkopen.2022.34200","article-title":"Comparative outcomes and safety of Vedolizumab vs tumor necrosis factor antagonists for older adults with inflammatory bowel diseases","volume":"5","author":"Singh","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026093014384415700_izag072-B37","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.cgh.2021.08.047","article-title":"Vedolizumab is associated with a lower risk of serious infections than anti-tumor necrosis factor agents in older adults","volume":"20","author":"Kochar","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026093014384415700_izag072-B38","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/ibd\/izae174","article-title":"Comparative safety and effectiveness of Ustekinumab and anti-TNF in elderly Crohn\u2019s disease patients","volume":"31","author":"Gebeyehu","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026093014384415700_izag072-B39","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s10620-022-07770-8","article-title":"Ustekinumab and Vedolizumab are equally safe and effective in elderly Crohn\u2019s disease patients","volume":"68","author":"Gebeyehu","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2026093014384415700_izag072-B40","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.cgh.2020.12.030","article-title":"Risk of serious infections with Vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease","volume":"20","author":"Kirchgesner","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/10\/1888\/68248939\/izag072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/10\/1888\/68248939\/izag072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:38:50Z","timestamp":1790793530000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/10\/1888\/8672838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5,8]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag072","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,5,8]]}}}